Type 3 cystatins; fetuins, kininogen and histidine-rich glycoprotein

Frontiers in Bioscience

Volumn 14, Issue 8, 2009, Pages 2911-2922

  Lee, Chunsik ^a   Bongcam Rudloff, Erik ^b   Sollner, Christian ^c   Jahnen Dechent, Willi ^d   Claesson Welsh, Lena ^a,e  

^a UPPSALA UNIVERSITY   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Angiogenesis; Bradykinin; Cystatins; Fetuin; Histidine rich glycoprotein; Kininogen; Kininostatin; Mineralization; Review; Tumor supressor

Indexed keywords

CYSTATIN;

CHEMISTRY; CHROMOSOME MAP; GENETICS; HUMAN; PHYSIOLOGY; PROTEIN CONFORMATION; REVIEW;

CHROMOSOME MAPPING; CYSTATINS; HUMANS; PROTEIN CONFORMATION;

EID: 63849098507     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2735/3422     Document Type: Review

References (67)

1. Abrahamson, M., M. Alvarez-Fernandez & C. M. Nathanson: Cystatins. Biochem Soc Symp179-99 (2003).
2. Mellgren, R. L. & X. Huang: Fetuin A stabilizes mcalpain and facilitates plasma membrane repair. J Biol Chem, 282, 35868-77 (2007). (Pubitemid 350277142)
3. Westenfeld, R., W. Jahnen-Dechent & M. Ketteler: Vascular calcification and fetuin-A deficiency in chronic kidney disease. Trends Cardiovasc Med, 17, 124-8 (2007). (Pubitemid 46670022)
4. Denecke, B., S. Graber, C. Schafer, A. Heiss, M. Woltje & W. Jahnen-Dechent: Tissue distribution and activity testing suggest a similar but not identical function of fetuin- B and fetuin-A. Biochem J, 376, 135-45 (2003). (Pubitemid 37487209)
5. Swallow, C. J., E. A. Partridge, J. C. Macmillan, T. Tajirian, G. M. DiGuglielmo, K. Hay, M. Szweras, W. Jahnen-Dechent, J. L. Wrana, M. Redston, S. Gallinger & J. W. Dennis: alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression. Cancer Res, 64, 6402-9 (2004). (Pubitemid 39297893)
6. Kundranda, M. N., M. Henderson, K. J. Carter, L. Gorden, A. Binhazim, S. Ray, T. Baptiste, M. Shokrani, M. L. Leite-Browning, W. Jahnen-Dechent, L. M. Matrisian & J. Ochieng: The serum glycoprotein fetuin-A promotes Lewis lung carcinoma tumorigenesis via adhesivedependent and adhesive-independent mechanisms. Cancer Res, 65, 499-506 (2005).
7. Hsu, S. J., H. Nagase & A. Balmain: Identification of Fetuin-B as a member of a cystatin-like gene family on mouse chromosome 16 with tumor suppressor activity. Genome, 47, 931-46 (2004). (Pubitemid 40033906)
8. Bhoola, K. D., C. D. Figueroa & K. Worthy: Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev, 44, 1-80 (1992).
9. Merkulov, S., W. M. Zhang, A. A. Komar, A. H. Schmaier, E. Barnes, Y. Zhou, X. Lu, T. Iwaki, F. J. Castellino, G. Luo & K. R. McCrae: Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood, 111, 1274-81 (2008). (Pubitemid 351213410)
10. Tsuchida-Straeten, N., S. Ensslen, C. Schafer, M. Woltje, B. Denecke, M. Moser, S. Graber, S. Wakabayashi, T. Koide & W. Jahnen-Dechent: Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost, 3, 865-72 (2005). (Pubitemid 41632812)
11. Bruford, E. A., M. J. Lush, M. W. Wright, T. P. Sneddon, S. Povey & E. Birney: The HGNC Database in 2008: a resource for the human genome. Nucleic Acids Res, 36, D445-8 (2008). (Pubitemid 351149764)
12. Osawa, M., W. Tian, H. Horiuchi, M. Kaneko & K. Umetsu: Association of alpha2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet, 116, 146-51 (2005). (Pubitemid 40173998)
13. Olivier, E., E. Soury, P. Ruminy, A. Husson, F. Parmentier, M. Daveau & J. P. Salier: Fetuin-B, a second member of the fetuin family in mammals. Biochem J, 350 Pt 2, 589-97 (2000).
14. Hennis, B. C., P. A. van Boheemen, S. Wakabayashi, T. Koide, J. J. Hoffmann, P. Kievit, G. Dooijewaard, J. G. Jansen & C. Kluft: Identification and genetic analysis of a common molecular variant of histidine-rich glycoprotein with a difference of 2kD in apparent molecular weight. Thromb Haemost, 74, 1491-6 (1995). (Pubitemid 26018076)
15. Wakabayashi, S., H. Yoshida, T. Shigekiyo & T. Koide: Intracellular degradation of histidine-rich glycoprotein mutants: tokushima-1 and 2 mutants are degraded by different proteolytic systems. J Biochem, 128, 201-6 (2000).
16. Shigekiyo, T., H. Yoshida, Y. Kanagawa, K. Satoh, S. Wakabayashi, T. Matsumoto & T. Koide: Histidine-rich glycoprotein (HRG) Tokushima 2: novel HRG deficiency, molecular and cellular characterization. Thromb Haemost, 84, 675-9 (2000).
17. Heiss, A., T. Eckert, A Aretz, W. Richtering, W. van Dorp, C. Schafer, & W. Jahnen-Dechent. Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J Biol Chem, 283, 14815-25 (2008).
18. Jahnen-Dechent, W., A. Trindl, J. Godovac- Zimmermann & W. Muller-Esterl: Posttranslational processing of human alpha 2-HS glycoprotein (human fetuin). Evidence for the production of a phosphorylated single-chain form by hepatoma cells. Eur J Biochem, 226, 59-69 (1994) (Pubitemid 24348669)
19. Haglund, A. C., B. Ek & P. Ek: Phosphorylation of human plasma alpha2-Heremans-Schmid glycoprotein (human fetuin) in vivo. Biochem J, 357, 437-45 (2001). (Pubitemid 32701780)
20. Auberger, P., L. Falquerho, J. O. Contreres, G. Pages, G. Le Cam, B. Rossi & A. Le Cam: Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell, 58, 631-40 (1989). (Pubitemid 19210957)
21. Kubler, D., D. Gosenca, M. Wind, H. Heid, I. Friedberg, W. Jahnen-Dechent & W. D. Lehmann: Proteolytic processing by matrix metalloproteinases and phosphorylation by protein kinase CK2 of fetuin-A, the major globulin of fetal calf serum. Biochimie, 89, 410-8 (2007). (Pubitemid 46442762)
22. Colman, R. W. & A. H. Schmaier: Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood, 90, 3819-43 (1997). (Pubitemid 27484034)
23. Chavakis, T., S. M. Kanse, F. Lupu, H. P. Hammes, W. Muller-Esterl, R. A. Pixley, R. W. Colman & K. T. Preissner: Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin and urokinase receptor-dependent interactions. Blood, 96, 514-22 (2000). (Pubitemid 30463370)
24. Tompa, P.: Intrinsically unstructured proteins. Trends Biochem Sci, 27, 527-33 (2002). (Pubitemid 35279598)
25. Maret, W.: Zinc coordination environments in proteins determine zinc functions. J Trace Elem Med Biol, 19, 7-12 (2005). (Pubitemid 41258175)
26. Dziegielewska K. M. & W. M. Brown. Fetuin (Heidelberg: Springer-Verlag GmbH; 1995).
27. Lebreton, J. P., F. Joisel, J. P. Raoult, B. Lannuzel, J. P. Rogez & G. Humbert: Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acutephase reactant. J Clin Invest, 64, 1118-29 (1979). (Pubitemid 10232592)
28. Ribom, D., A. Westman-Brinkmalm, A. Smits & P. Davidsson: Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas. Tumour Biol, 24, 94-9 (2003). (Pubitemid 36829119)
29. Sainz, I. M., R. A. Pixley & R. W. Colman: Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost, 98, 77-83 (2007). (Pubitemid 47074181)
30. van Iwaarden, F., P. G. de Groot & B. N. Bouma: The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem, 263, 4698-703 (1988).
31. Saito, H., L. T. Goodnough, J. M. Boyle & N. Heimburger: Reduced histidine-rich glycoprotein levels in plasma of patients with advanced liver cirrhosis. Possible implications for enhanced fibrinolysis. Am J Med, 73, 179- 82 (1982). (Pubitemid 13203912)
32. Morgan, W. T.: Human serum histidine-rich glycoprotein. I. Interactions with heme, metal ions and organic ligands. Biochim Biophys Acta, 535, 319-33 (1978). (Pubitemid 8388673)
33. Corrigan, J. J. Jr., M. A. Jeter, D. Bruck & W. M. Feinberg: Histidine-rich glycoprotein levels in children: the effect of age. Thromb Res, 59, 681-6 (1990). (Pubitemid 20330348)
34. Leung, L. L., P. C. Harpel, R. L. Nachman & E. M. Rabellino: Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood, 62, 1016-21 (1983). (Pubitemid 14237323)
35. Halbmayer, W. M., P. Hopmeier, C. Feichtinger, K. Rubi & M. Fischer: Histidine-rich glycoprotein (HRG) in uncomplicated pregnancy and mild and moderate preeclampsia. Thromb Haemost, 67, 585-6 (1992).
36. Morgan, W. T.: Serum histidine-rich glycoprotein levels are decreased in acquired immune deficiency syndrome and by steroid therapy. Biochem Med Metab Biol, 36, 210-3 (1986). (Pubitemid 16008492)
37. Leebeek, F. W., C. Kluft, E. A. Knot & M. P. De Maat: Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis. J Lab Clin Med, 113, 493-7 (1989). (Pubitemid 19109409)
38. Jones, A. L., M. D. Hulett & C. R. Parish: Histidinerich glycoprotein: A novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol Cell Biol, 83, 106-18 (2005). (Pubitemid 40469318)
39. Vanwildemeersch, M., A. K. Olsson, E. Gottfridsson, L. Claesson-Welsh, U. Lindahl & D. Spillmann: The antiangiogenic His/Pro-rich fragment of histidine-rich glycoprotein binds to endothelial cell heparan sulfate in a Zn2+-dependent manner. J Biol Chem, 281, 10298-304 (2006). (Pubitemid 43864568)
40. Schinke, T., C. Amendt, A. Trindl, O. Poschke, W. Muller-Esterl & W. Jahnen-Dechent: The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem, 271, 20789-96 (1996). (Pubitemid 26281865)
41. Reynolds, J. L., J. N. Skepper, R. McNair, T. Kasama, K. Gupta, P. L. Weissberg, W. Jahnen-Dechent & C. M. Shanahan: Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol, 16, 2920-30 (2005). (Pubitemid 44743490)
42. Rittenberg, B., E. Partridge, G. Baker, C. Clokie, R. Zohar, J. W. Dennis & H. C. Tenenbaum: Regulation of BMP-induced ectopic bone formation by Ahsg. J Orthop Res, 23, 653-62 (2005). (Pubitemid 40631339)
43. Szweras, M., D. Liu, E. A. Partridge, J. Pawling, B. Sukhu, C. Clokie, W. Jahnen-Dechent, H. C. Tenenbaum, C. J. Swallow, M. D. Grynpas & J. W. Dennis: alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem, 277, 19991-7 (2002). (Pubitemid 34967522)
44. Schafer, C., A. Heiss, A. Schwarz, R. Westenfeld, M. Ketteler, J. Floege, W. Muller-Esterl, T. Schinke & W. Jahnen-Dechent: The serum protein alpha 2-Heremans- Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest, 112, 357-66 (2003). (Pubitemid 38063764)
45. Merx, M. W., C. Schafer, R. Westenfeld, V. Brandenburg, S. Hidajat, C. Weber, M. Ketteler & W. Jahnen-Dechent: Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-Adeficient mice. J Am Soc Nephrol, 16, 3357-64 (2005). (Pubitemid 46179339)
46. Jahnen-Dechent, W., C. Schafer, M. Ketteler & M. D. McKee: Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. J Mol Med. Prepub online Dec 5 (2007).
47. Srinivas, P. R., A. S. Wagner, L. V. Reddy, D. D. Deutsch, M. A. Leon, A. S. Goustin & G. Grunberger: Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol, 7, 1445-55 (1993).
48. Rydengard, V., A. K. Olsson, M. Morgelin & A. Schmidtchen: Histidine-rich glycoprotein exerts antibacterial activity. Febs J, 274, 377-89 (2007). (Pubitemid 46046648)
49. Rydengard, V., E. Andersson Nordahl & A. Schmidtchen: Zinc potentiates the antibacterial effects of histidine-rich peptides against Enterococcus faecalis. Febs J, 273, 2399-406 (2006). (Pubitemid 43736654)
50. Bosshart, H. & M. Heinzelmann: Endotoxinneutralizing effects of histidine-rich peptides. FEBS Lett, 553, 135-40 (2003).
51. Chavakis, T. & K. T. Preissner: Potential pharmacological applications of the antithrombotic molecule high molecular weight kininogen. Curr Vasc Pharmacol, 1, 59-64 (2003).
52. Madeddu, P., C. Emanueli & S. El-Dahr: Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling. Nat Clin Pract Nephrol, 3, 208-21 (2007). (Pubitemid 46496868)
53. Zhang, J. C., K. Claffey, R. Sakthivel, Z. Darzynkiewicz, D. E. Shaw, J. Leal, Y. C. Wang, F. M. Lu & K. R. McCrae: Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. Faseb J, 14, 2589-600 (2000).
54. Katkade, V., A. A. Soyombo, I. Isordia-Salas, H. N. Bradford, J. P. Gaughan, R. W. Colman & T. S. Panetti: Domain 5 of cleaved high molecular weight kininogen inhibits endothelial cell migration through Akt. Thromb Haemost, 94, 606-14 (2005). (Pubitemid 41300859)
55. Colman, R. W.: Regulation of angiogenesis by the kallikrein-kinin system. Curr Pharm Des, 12, 2599-607 (2006).
56. Sun, D. & K. R. McCrae: Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species. Blood, 107, 4714-20 (2006). (Pubitemid 43882621)
57. Wu, Y., V. Rizzo, Y. Liu, I. M. Sainz, N. G. Schmuckler & R. W. Colman: Kininostatin associates with membrane rafts and inhibits alpha(v)beta3 integrin activation in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol, 27, 1968-75 (2007). (Pubitemid 47312306)
58. Zhang, J. C., F. Donate, X. Qi, N. P. Ziats, J. C. Juarez, A. P. Mazar, Y. P. Pang & K. R. McCrae: The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci U S A, 99, 12224-9 (2002).
59. Juarez, J. C., X. Guan, N. V. Shipulina, M. L. Plunkett, G. C. Parry, D. E. Shaw, J. C. Zhang, S. A. Rabbani, K. R. McCrae, A. P. Mazar, W. T. Morgan & F. Donate: Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidineproline- rich domain. Cancer Res, 62, 5344-50 (2002). (Pubitemid 35024611)
60. Olsson, A. K., H. Larsson, J. Dixelius, I. Johansson, C. Lee, C. Oellig, I. Bjork & L. Claesson-Welsh: A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res, 64, 599-605 (2004). (Pubitemid 38120899)
61. Dixelius, J., A. K. Olsson, A. Thulin, C. Lee, I. Johansson & L. Claesson-Welsh: Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein. Cancer Res, 66, 2089-97 (2006).
62. Lee, C., J. Dixelius, A. Thulin, H. Kawamura, L. Claesson-Welsh & A. K. Olsson: Signal transduction in endothelial cells by the angiogenesis inhibitor histidine-rich glycoprotein targets focal adhesions. Exp Cell Res, 312, 2547-56 (2006). (Pubitemid 44036805)
63. Donate, F., J. C. Juarez, X. Guan, N. V. Shipulina, M. L. Plunkett, Z. Tel-Tsur, D. E. Shaw, W. T. Morgan & A. P. Mazar: Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities. Cancer Res, 64, 5812-7 (2004). (Pubitemid 39095581)
64. Guan, X., J. C. Juarez, X. Qi, N. V. Shipulina, D. E. Shaw, W. T. Morgan, K. R. McCrae, A. P. Mazar & F. Donate: Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb Haemost, 92, 403-12 (2004). (Pubitemid 39172321)
65. Simantov, R., M. Febbraio, R. Crombie, A. S. Asch, R. L. Nachman & R. L. Silverstein: Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J Clin Invest, 107, 45-52 (2001). (Pubitemid 32047413)
66. Edgar, R. C.: MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res, 32, 1792-7 (2004). (Pubitemid 38832724)
67. Hubbard, T. J., B. L. Aken, K. Beal, B. Ballester, M. Caccamo, Y. Chen, L. Clarke, G. Coates, F. Cunningham, T. Cutts, T. Down, S. C. Dyer, S. Fitzgerald, J. Fernandez-Banet, S. Graf, S. Haider, M. Hammond, J. Herrero, R. Holland, K. Howe, N. Johnson, A. Kahari, D. Keefe, F. Kokocinski, E. Kulesha, D. Lawson, I. Longden, C. Melsopp, K. Megy, P. Meidl, B. Ouverdin, A. Parker, A. Prlic, S. Rice, D. Rios, M. Schuster, I. Sealy, J. Severin, G. Slater, D. Smedley, G. Spudich, S. Trevanion, A. Vilella, J. Vogel, S. White, M. Wood, T. Cox, V. Curwen, R. Durbin, X. M. Fernandez-Suarez, P. Flicek, A. Kasprzyk, G. Proctor, S. Searle, J. Smith, A. Ureta-Vidal & E. Birney: Ensembl 2007. Nucleic Acids Res, 35, D610-7 (2007). (Pubitemid 46056279)